Paul was a coach, advocate, and one of the leading voices for the HEALing Communities Study
NIH study highlights the need to expand buprenorphine-based treatment while monitoring and reducing misuse
New guidance for researchers establishes a standard THC unit of 5 milligrams.
Looks at the challenges with substance use disorders (SUDs) among people in the criminal justice system, and why treatment and follow up is important for inmates.
Naloxone can quickly restore normal breathing to a person during an opioid overdose.
New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease.
One of the pillars of the current federal initiatives to end the opioid crisis is the development of new medications to treat opioid addiction. The FDA Patient-Focused Drug Development Initiative (PFDD), established in 2012, seeks to solicit patient perspectives on which symptoms are most important to target.
This week, the Food and Drug Administration (FDA) approved lofexidine, the first medication targeted specifically to treat the physical symptoms associated with opioid withdrawal.
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving will go toward the goal of addressing addiction in new ways and better delivering existing forms of care to populations that need it.
Subscribe to Treatment Research
This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders.